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The replication of enteroviruses is sensitive to brefeldin A (BFA), an inhibitor of endoplasmic reticulum-
to-Golgi network transport that blocks activation of guanine exchange factors (GEFs) of the Arf GTPases.
Mammalian cells contain three BFA-sensitive Arf GEFs: GBF1, BIG1, and BIG2. Here, we show that coxsack-
ievirus B3 (CVB3) RNA replication is insensitive to BFA in MDCK cells, which contain a BFA-resistant GBF1
due to mutation M832L. Further evidence for a critical role of GBF1 stems from the observations that viral
RNA replication is inhibited upon knockdown of GBF1 by RNA interference and that replication in the
presence of BFA is rescued upon overexpression of active, but not inactive, GBF1. Overexpression of Arf
proteins or Rab1B, a GTPase that induces GBF1 recruitment to membranes, failed to rescue RNA replication
in the presence of BFA. Additionally, the importance of the interaction between enterovirus protein 3A and
GBF1 for viral RNA replication was investigated. For this, the rescue from BFA inhibition of wild-type (wt)
replicons and that of mutant replicons of both CVB3 and poliovirus (PV) carrying a 3A protein that is impaired
in binding GBF1 were compared. The BFA-resistant GBF1-M832L protein efficiently rescued RNA replication
of both wt and mutant CVB3 and PV replicons in the presence of BFA. However, another BFA-resistant GBF1
protein, GBF1-A795E, also efficiently rescued RNA replication of the wt replicons, but not that of mutant
replicons, in the presence of BFA. In conclusion, this study identifies a critical role for GBF1 in CVB3 RNA
replication, but the importance of the 3A-GBF1 interaction requires further study.
Enteroviruses are small, nonenveloped, positive-stranded
RNA viruses that include many important pathogens, such as
poliovirus (PV), coxsackievirus, echovirus, and human rhinovirus.
Following virus entry and uncoating, the 7.5-kb enteroviral RNA
genome is directly translated into a large polyprotein. This
polyprotein is proteolytically processed by the virus-encoded pro-
teases 2Apro, 3Cpro, and 3CDpro into the structural P1 region
proteins and the nonstructural P2 and P3 region proteins that are
involved in viral RNA replication.
All RNA viruses with a positive-stranded genome induce the
remodeling of cellular membranes to create a scaffold for
genomic RNA replication. The organelle origin and morphol-
ogy of these membranous replication sites, however, appear to
vary for different viruses. Enteroviruses replicate their RNA
genomes in nucleoprotein complexes that are associated with
small vesicular membrane structures (6). The enteroviral pro-
teins 2B, 2C, and 3A have been implicated in vesicle formation
(4, 6, 27), but the mechanism and pathway of membrane re-
organization are poorly understood. There are strong indica-
tions that these vesicular membranous structures, which are
referred to here as “vesicles,” are derived from the early se-
cretory pathway. Vesicles produced in PV-infected cells may
form at the endoplasmic reticulum (ER) by the cellular COP-II
budding machinery and may therefore share components with
the membranous vesicles mediating ER-to-Golgi network
transport (26). Further support for the involvement of the
secretory pathway stems from the observation that brefeldin A
(BFA), a well-known inhibitor of ER-to-Golgi network trans-
port, completely inhibits enteroviral RNA replication (17, 20).
In addition, the autophagocytic pathway appears to contribute
to the formation of the membrane vesicles, many of which
exhibit a double-membrane morphology characteristic of auto-
phagosomes (18, 27). The utilization of individual components
or reactions from different membrane metabolic pathways,
rather than subversion of an entire pathway in toto, may
represent a common strategy for building viral replication
machinery.
BFA inhibits activation of the small monomeric GTPase
ADP ribosylation factor 1 (Arf1), a major regulator of intra-
cellular protein transport (2). Arf1 cycles between an inactive,
GDP-bound, cytosolic state and an active, GTP-bound, mem-
brane-associated state, and this cycling is catalyzed by guanine
nucleotide exchange factors (GEFs) and GTPase-activating
proteins (13). BFA blocks the activities of the large GEFs
GBF1, BIG1, and BIG2 by stabilizing an intermediate, abor-
tive complex with inactive Arf1 (23), thus efficiently preventing
activation of Arf1 and eventually formation of transport inter-
mediates.
* Corresponding author. Mailing address: Department of Medical
Microbiology, Nijmegen Centre for Molecular Life Sciences and Ni-
jmegen Institute for Infection, Inflammation and Immunity, Radboud
University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijme-
gen, The Netherlands. Phone: 31-24-3617574. Fax: 31-24-3614666. E-
mail: f.vankuppeveld@ncmls.ru.nl.
† Present address: Department of Medical Microbiology, Radboud
University Nijmegen Medical Centre, Nijmegen, The Netherlands.
‡ Present address: Yacht BV, Eindhoven, The Netherlands.
 Published ahead of print on 9 September 2009.
11940
 o
n
 July 11, 2012 by Universiteitsbibliotheek
http://jvi.asm.org/
D
ow
nloaded from
 
Not only the fact that BFA blocks enteroviral replication
suggests a role for Arf1 and/or its large GEFs in this process;
recently, it was shown that Arf1 accumulates on membranes
during PV infection (3). Arf1 translocation to membranes can
be induced independently by enterovirus protein 3A or 3CD in
vitro (5), but the underlying mechanisms seem to differ; the 3A
protein specifically triggers the recruitment of GBF1 to mem-
branes, most likely through a direct interaction with this GEF
(32, 33), whereas 3CD recruits BIG1 and BIG2 to membranes
(3). Here, we report the involvement of Arf1 and its large
BFA-sensitive GEFs in coxsackievirus B3 (CVB3) replication.
MATERIALS AND METHODS
Cells and reagents. Buffalo green monkey (BGM) kidney cells and HeLa cells
were grown in minimal essential medium (Gibco) supplemented with 10% fetal
bovine serum (FBS). Madin-Darby canine kidney (MDCK) cells were main-
tained in Dulbecco’s minimum essential medium (Gibco) supplemented with
10% FBS. The cells were grown at 37°C in a 5% CO2 incubator. BFA was
purchased from Sigma-Aldrich and was used, unless otherwise stated, at a final
concentration of 2 g/ml.
Viruses and replicons. The CVB3 used in this study was derived from the
p53CB3/T7 plasmid, which contains the cDNA of CVB3 strain Nancy driven by
a T7 RNA polymerase promoter (34). CVB3 expressing either Renilla luciferase
(RLuc-CVB3) or enhanced green fluorescent protein (EGFP-CVB3) were ob-
tained by placing the Renilla luciferase or EGFP coding sequences, followed by
a 3CD cleavage site, between the 5 untranslated region and the P1 coding
region. Virus yields were determined by end-point titration according to the
method of Reed and Muench and expressed as 50% tissue culture infective doses
(TCID50) (24). The CVB3 replicons pRib-CB3-LUC and pRib-CB3-RLUC con-
tain a CVB3 cDNA in which the P1 capsid coding region has been replaced by
the firefly luciferase gene or the Renilla luciferase gene, respectively. The cDNA
was placed behind a hammerhead ribozyme coding sequence to remove 5-end
extra nucleotides. The encephalomyocarditis virus (EMCV) replicon pE-Luc (1)
and the PV replicons pXpA-RenR and pXpA-RenR 3A-2 (4) have been de-
scribed previously.
Plasmids. Plasmids pEYFP-GBF1 wild type (wt), M832L, E794K, Sec7 (22),
A795E (4), and pRab1b-EGFP wt and the Q67L mutant (21) have been previ-
ously described. Enhanced yellow fluorescent protein (EYFP)-tagged versions of
the different Arf isoforms have been described previously (14). Q71L versions of
these EYFP-tagged Arf isoforms were constructed by site-directed mutagenesis.
Plasmid pCMV-Gluc, which expresses secreted Gaussia luciferase, was pur-
chased from New England Biolabs.
Virus infection and BFA rescue experiments. Confluent monolayers of BGM
or HeLa cells were infected with virus for 30 min at 37°C at a multiplicity of
infection (MOI) of 10 TCID50 per cell. The cells were then washed twice with
phosphate-buffered saline and cultured in minimal essential medium supple-
mented with 10% FBS, with or without BFA, at 37°C for the indicated periods
of time. At the indicated times, the cells were disrupted by three cycles of
freezing and thawing, and virus titers were determined by end-point titration. For
the rescue experiments, BGM or HeLa cells were grown in 24-well plates to
subconfluence and transfected with 200 ng plasmid DNA using GeneJuice Trans-
fection reagent (Novagen) according to the manufacturer’s instructions. At 16 h
posttransfection, the cells were infected with virus at an MOI of 10 as described
above.
Replicon assays. Replicons were linearized, purified, and transcribed in vitro
by T7 RNA polymerase, and transcript RNAs were transfected into cells as
described previously (4, 28). After transfection, the cells were cultured in me-
dium with or without BFA at 37°C. At the indicated times posttransfection, the
cells were lysed and luciferase activity was assayed as described previously (4, 28).
Immunofluorescence. MDCK cells grown to subconfluence on coverslips in
24-well plates were treated with BFA for 2 h at 37°C and stained with polyclonal
anti-COP-I (against - and -COP) antiserum (diluted 1:200; from K. Frey and
F. Wieland, Biochemie-Zentrum, Heidelberg, Germany) or monoclonal anti-
adaptin (AP-1) antiserum (diluted 1:100; Sigma). Alexa Fluor 594-conjugated
goat anti-rabbit immunoglobulin G and Alexa Fluor 488-conjugated anti-mouse
immunoglobulin G were obtained from Molecular Probes. Pictures were taken
with a Leica TCS NT microscope (Leica Lasertechnik GmbH, Heidelberg, Ger-
many).
siRNA treatments. HeLa Kyoto cells were plated at 40% to 50% confluence in
24-well plates, with or without coverslips, and transfected with 50 pmol of small
interfering RNA (siRNA) using Oligofectamine (Invitrogen) according to the
manufacturer’s protocol. The siRNAs directed against GBF1 and Arf were from
Qiagen (identifier, SI00425411) and Ambion (identifier, 10237), respectively. At
40 h posttransfection, the cells were infected with either a Renilla luciferase
(RLuc-CVB3)- or EGFP (EGFP-CVB3)-expressing virus at an MOI of 5
TCID50 per cell. At 7 h postinfection, the cells were either fixed and Hoechst
counterstained before the fluorescent cells were counted, or the cells were lysed
in Renilla lysis buffer and the luciferase activity was assayed as described previ-
ously (28).
Immunoblotting. Protein samples were run on a NuPage 4 to 12% N,N-
methylenebisacrylamide–Tris gradient gel (Invitrogen) and transferred to a ni-
trocellulose membrane (Bio-Rad). EYFP fusion proteins were stained with the
anti-EGFP polyclonal antiserum (dilution 1:10,000) (10) or anti-EGFP mono-
clonal antibodies (Becton Dickinson).
Secretion rescue assay. HeLa cells were plated at 40,000 per well in a 96-well
plate and transfected with pGEM (control), pEYFP-GBF1 M832L, or pEYFP-
GBF1 A795E and pCMV-Gluc with Lipofectamine LTX (Invitrogen). The next
day, the cells were washed and incubated with medium containing 1 g/ml BFA
for 5 h. A portion of the medium was tested for secreted luciferase activity with
the Gaussia Luciferase assay kit (New England Biolabs).
BFA toxicity assay. HeLa cells were plated at 20,000 per well in a 96-well plate
and transfected with pGEM, pEYFP-GBF1 M832L, or pEYFP-GBF1 with
Lipofectamine LTX. The next day, the cells were incubated in medium contain-
ing the indicated amount of BFA. The medium was changed at regular intervals
to ensure constant pressure of the inhibitor. Cell viability was determined at 2
days posttransfection using the Cell Titer-Glo luminescence cell viability assay kit
(Promega).
RESULTS
GBF1 activity, but not BIG1 or BIG2 activity, is required for
CVB3 RNA replication in MDCK cells. BFA inhibits the three
large Arf GEFs GBF1, BIG1, and BIG2 (Fig. 1A) by binding
to and stabilizing transient complexes between the GEF and an
inactive, GDP-bound Arf. To determine the relative contribu-
tions of the individual GEFs to viral replication, we investi-
gated CVB3 RNA replication in MDCK cells. The sequence of
the dog genome indicates a naturally occurring mutation in the
Sec7 domain of GBF1 (M832L) that is predicted to render it
insensitive to BFA (22), whereas BIG1 and BIG2 in these cells
are predicted to be BFA sensitive (19) (Fig. 1A). Sequence
analysis of the Sec7 domain of the MDCK cell line that was
used in our study confirmed the occurrence of the M832L
mutation (data not shown). The resistance of GBF1 in these
cells to BFA was demonstrated by immunofluorescence stud-
ies. GBF1 mainly resides in the cis-Golgi, where it activates
Arf1 to recruit COP-I, whereas BIG1 and BIG2 mainly reside
in the trans-Golgi network (TGN) and endosomes, where they
activate Arf1 to recruit AP-1. Due to this compartmentaliza-
tion, BFA treatment of MDCK cells caused AP-1 to dissociate
from TGN and endosomal membranes, whereas COP-I re-
mained associated with cis-Golgi membranes (Fig. 1B) (35),
consistent with a resistance of GBF1, but not BIG1 and BIG2,
to BFA.
CVB3 cannot infect MDCK cells (data not shown), most
likely due to absence of the receptor on the cell surface. There-
fore, we transfected these cells with a subgenomic replicon of
CVB3 containing the firefly luciferase gene in place of the P1
coding region (pRib-CB3-LUC). The amount of luciferase ac-
tivity produced by this replicon is a measure of viral-RNA
replication. MDCK cells transfected with RNA transcripts of
the CVB3 replicon were incubated for the indicated periods of
time in the presence or absence of BFA or guanidine-HCl, a
well-known inhibitor of enterovirus replication (25). Analysis
of the luciferase activity showed that CVB3 replicates effi-
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ciently in the presence of BFA in MDCK cells, whereas rep-
lication was completely blocked by BFA in HeLa cells (Fig.
1C). Since GBF1 is the only GEF resistant to BFA in MDCK
cells, this indicates a role for GBF1, but not for BIG1 and
BIG2, in CVB3 replication.
Knockdown of GBF1, but not Arf1, reduces CVB3 replica-
tion in HeLa cells. Thus far, the potential roles of host cell
proteins in CVB3 replication had been studied in the presence
of BFA. To further explore the possible requirement for GBF1
and Arf1 in CVB3 replication, HeLa cells were depleted of
GBF1 or Arf1 by treatment with specific siRNAs. Analysis of
the efficiency of knockdown with an antibody against GBF1
showed that siRNA treatment reduced the expression of the
protein in 80% to 90% of the cells (Fig. 2A). Due to the lack
of commercial antibody that specifically recognizes Arf1, but
not the other Arf isoforms, another procedure was employed
to demonstrate the efficiency of the Arf1 siRNA treatment.
For this, cells were transfected with plasmids expressing an
EYFP fusion of either GBF1 or Arf1, together with siRNAs
against GBF1 or Arf1. The fluorescence of EYFP-Arf1 and
EYFP-GBF1 was lost after cotransfection with the correspond-
ing siRNA, showing that the knockdown was efficient (Fig. 2B).
No reduction of EYFP-Arf1 or EYFP-GBF1 fluorescence was
observed upon cotransfection of a scrambled control siRNA.
To examine the effects of the knockdowns on CVB3 RNA
replication, we made use of recombinant viruses expressing
either EGFP (EGFP-CVB3) or Renilla luciferase (RLuc-
CVB3). These foreign sequences were inserted between the 5
untranslated region and the capsid-coding region and were
followed by a 3CDpro cleavage site to allow proteolytic pro-
cessing of the foreign proteins from the viral polyprotein.
These viruses showed efficient RNA replication, but virus pro-
duction was impaired relative to wt virus, due to inefficient
liberation of the foreign proteins from the viral polyprotein
and/or inefficient packaging of the viral RNAs containing the
insert. The amount of fluorescence or luciferase activity is a
FIG. 1. BFA does not affect CVB3 RNA replication in MDCK cells, which contain a BFA-resistant GBF1 protein. (A) Schematic represen-
tation of the three BFA-sensitive Arf GEFs. The BFA-resistant mutation in the Sec7 domain of GBF1 in MDCK cells is indicated in boldface.
(B) Control MDCK cells and cells treated with 2 g/ml BFA were stained with antibodies against COP-I or AP1. Note that BFA has no effect on
the association of COP-I with Golgi membranes but causes the dissociation of AP1 from the TGN and endosomes in MDCK cells. (C) MDCK
cells and HeLa cells were transfected with in vitro RNA transcripts derived from a cDNA encoding a CB3 replicon containing the firefly luciferase
gene in place of the P1 capsid coding region. After transfection, the cells were supplied with medium containing BFA or guanidine-HCl, a well
known inhibitor of enterovirus RNA replication. Luciferase production was measured at the indicated time points.
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good measure of viral RNA replication. HeLa cells were
treated with siRNA for 40 h, infected with either EGFP-CVB3
or RLuc-CVB3, and analyzed at 7 h postinfection. Treatment
of cells with GBF1 siRNA reduced the relative number of
fluorescent cells (Fig. 2C), as well as the amount of luciferase
produced (Fig. 2D). No inhibition of CVB3 replication was
observed upon Arf1 knockdown; the number of fluorescent
cells (Fig. 2C) and the levels of luciferase in cells treated with
Arf1 siRNA (Fig. 2D) were similar to those in control siRNA-
treated cells. To exclude the possibility that the inhibitory
effect of GBF1 depletion on CVB3 replication is due to a
general toxic effect on the cells, RNA replication levels of
FIG. 2. siRNA-mediated knockdown of GBF1, but not of Arf1, inhibits CVB3 RNA replication in HeLa cells. (A) Cells were treated with
siRNA against GBF1 for 40 h and then stained with an antibody against GBF1. The siRNA treatment inhibited GBF1 expression in about
80 to 90% of the cells. (B) Cells were cotransfected with a plasmid encoding EYFP-GBF1 and siRNA against GBF1 (left) or cotransfected
with a plasmid encoding Arf1-EYFP and siRNA against Arf1. Fluorescence was monitored at 2 days posttransfection. (C) Cells were treated
with siRNAs directed against GBF1 or Arf1 or a scrambled siRNA (control). At 40 h posttransfection, the cells were infected with
GFP-expressing CVB3. GFP fluorescence, which is indicative of replication, was monitored at 7 h postinfection. (D) Similar to panel C, but
the cells were infected with a Renilla luciferase-expressing CVB3. Luciferase production was measured at 7 h postinfection and is expressed
as a percentage of that observed with the no-siRNA control (which was set at 100%). (E) Cells were treated with siRNAs against GBF1 or
a scrambled siRNA and then transfected with in vitro transcripts from firefly luciferase-expressing replicons of CVB3 or EMCV. The amount
of luciferase produced at 8 h posttransfection was measured and is expressed as a percentage of that observed with the siRNA control (which
was set at 100%).
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luciferase-expressing subgenomic replicons of CVB3 and
EMCV, a picornavirus whose replication is insensitive to BFA
(16), were compared. Figure 2E shows that the EMCV repli-
con (pE-Luc) replicated efficiently in GBF1 siRNA-treated
cells, whereas RNA replication of the CVB3 replicon (pRib-
CB3-LUC) was strongly reduced. The use of a replicon to
measure the effects on RNA synthesis additionally eliminated
virus adsorption, entry, and assembly processes as being re-
sponsible for the virus growth inhibition by GBF1 knockdown.
Collectively, these data show that GBF1 activity is crucial for
RNA replication of CVB3.
Overexpression of GBF1, but not Arf1 or Rab1B, rescues
CVB3 replication in the presence of BFA. Overexpression of
GBF1 has been shown to (partially) rescue PV replication in
the presence of BFA (3). To investigate whether overexpres-
sion of GBF1 could also rescue CVB3 replication in the pres-
ence of BFA, BGM cells were transfected with plasmid ex-
pressing EYFP-GBF1 or, as a control, EGFP prior to infection
in the presence or absence of BFA. In the absence of BFA,
CVB3 replication levels in cells transfected with EGFP and
EYFP-GBF1 were indistinguishable (data not shown). Figure
3A shows that overexpression of GBF1, but not EGFP, par-
tially rescued the effect of BFA on CVB3 replication (for
reasons of clarity, in this figure and subsequent figures, CVB3
replication in cultures transfected with only one of the con-
structs in the absence of BFA is shown). Overexpression of a
GBF1 protein containing mutation M832L (i.e., the mutation
that rendered MDCK cells resistant to BFA) resulted in a
much stronger rescue of the effects of BFA, as indicated by a
10-fold increase in the virus titer. Overexpression of inactive
GBF1 proteins, either lacking the catalytic Sec7 domain
(GBF1Sec7) or containing mutation E794K in this domain
(15), failed to rescue CVB3 replication in the presence of
BFA (Fig. 3A). Overexpression of BIG2 also failed to rescue
CVB3 replication in the presence of BFA (data not shown;
BIG1 was not tested since heterologous expression of this
protein in mammalian cells has not been successful). Similar
results were obtained in HeLa cells. Together, these data
suggest that active GBF1 is required to support CVB3 rep-
lication.
We also tested whether overexpression of Arf1 could rescue
CVB3 replication in the presence of BFA. Neither wt Arf1 nor
Arf1-Q71L, a constitutive active mutant of Arf1, could rescue
CVB3 replication in the presence of BFA (Fig. 3B). Similarly,
FIG. 3. GBF1, but not Arfs or Rab1B, rescues CVB3 replication in the presence of BFA. BGM cells were transfected with the indicated GBF1
expression constructs (A), with the indicated Arf1 or Rab1b expression constructs (B), or with combinations of different Arf isoforms (C). All of
the expressed proteins were GFP tagged. The next day, the cells were infected with CVB3 at an MOI of 10 and incubated at 37°C in medium with
or without BFA. At 8 h (C) or at 8 and 16 h (A and B) postinfection, the cells were lysed by three cycles of freezing and thawing, and the amount
of virus was determined by end-point titration. Western blot analysis using an anti-EGFP serum confirmed the expression of the indicated proteins.
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no rescue was observed upon overexpression of wt Arf3, Arf4,
or Arf5 or the dominant active Q71L mutants of these Arf
proteins (data not shown). Recently, evidence was presented
that different Arf isoforms act in pairs at distinct sites in the
secretory pathway (30). Therefore, we also tested whether
these different combinations of Arf isoforms (both the wt and
the constitutive active Q71L mutants) could rescue replication.
The results showed that neither of the tested combinations of
Arf isoforms could rescue CVB3 replication in the presence of
BFA (Fig. 3C).
Rab proteins, small GTPases, regulate membrane trans-
port between various compartments within eukaryotic cells.
Rab proteins regulate the formation, tethering, docking, and
fusion of vesicular membranes by recruiting and interacting
with downstream effector proteins. Rab1b interacts with the
N terminus of GBF1 and induces GBF1 recruitment at ER
exit sites and Golgi membranes (21). However, overexpres-
sion of neither wt Rab1B nor the constitutive active mutant
Rab1B-Q67L could rescue CVB3 replication in the presence
of BFA (Fig. 3B).
GBF1-M832L efficiently rescues replication of CVB3 carry-
ing a mutant 3A protein that is impaired in binding GBF1 in
the presence of BFA. The CVB3 3A protein has been shown to
interact with the N terminus of GBF1 (i.e., the region up-
stream of the catalytic Sec7 domain) (33). To investigate the
importance of this interaction for CVB3 replication, we ana-
lyzed the GBF1-mediated rescue of CVB3-3A-ins[16]S. This
virus, which shows delayed replication kinetics compared to wt
virus but which reaches a comparable titer after 8 h (31),
contains a serine insertion at amino acid position 16 in the 3A
protein. This mutant 3A protein showed a severely reduced
interaction with GBF1 (31). BGM cells transiently expressing
GBF1-M832L were infected with either CVB3 wt or the
CVB3-3A-ins[16]S mutant in the presence or absence of BFA,
and virus production was measured at 8 h postinfection. Figure
4 shows that replication of both wt CVB3 and the CVB3-3A-
ins[16]S mutant in the presence of BFA was efficiently rescued
by GBF1-M832L overexpression. Similar results were obtained
in HeLa cells (data not shown).
Differential rescue abilities of BFA-resistant GBF1 mutants
M832L and A795E. We have previously demonstrated that
GBF1 plays an important role in PV replication (4). In this
study, another BFA-resistant mutation in GBF1, mutation
A795E, was identified. This mutation was identified in a BFA-
resistant line of Vero cells. Overexpression of GBF1-A795E
rescued RNA replication of a wt PV replicon (pXpA-RenR) in
the presence of BFA. This GBF1 mutant, however, only poorly
rescued replication of a mutant PV replicon (mutant 3A-2)
carrying a serine insertion in the 3A protein at position 15
(which corresponds to the 3A-ins[16]S mutation in CVB3 3A).
Thus, a BFA-resistant GBF1 protein (M832L) efficiently res-
cued CVB3 carrying a 3A mutation with impaired GBF1 bind-
ing, whereas another BFA-resistant GBF1 protein (A795E)
did not efficiently rescue a PV replicon harboring the same 3A
mutation.
To elucidate the underlying reason for this apparent contra-
diction, we compared the RNA replication levels of both wt
and mutant Renilla luciferase-expressing CVB3 and PV repli-
cons in the presence or absence of BFA in cells transiently
expressing either GBF1-M832L or GBF1-A795E. Figure 5
shows that replications of the wt CVB3 replicon and the mu-
tant CVB3 replicon carrying mutation 3A-ins[16]S in the pres-
ence of BFA were equally well rescued by the GBF1-M832L
protein, consistent with the results shown in Fig. 4. GBF1-
A795E, however, rescued RNA replication of the wt CVB3
replicon to a significantly greater extent than that of the mu-
tant 3A-ins[16]S replicon, which was hardly rescued by this
GBF1 mutant. A similar trend was observed with the PV rep-
licons. Replication of both the wt PV replicon and the 3A-2
mutant replicon in the presence of BFA was efficiently rescued
by GBF1-M832L, whereas GBF1-A795E showed better rescue
of the wt replicon than of the mutant 3A-2 replicon. Thus, the
FIG. 4. GBF1-M832L efficiently rescues replication of CVB3 carrying a mutant 3A protein that is impaired in binding GBF1 in the presence
of BFA. BGM cells were transfected with EGFP (control) or EYFP-GBF1 M832L. The next day, the cells were infected with either wt CVB3
(A) or CVB3-3A-ins[16]S (B) at an MOI of 10 and incubated at 37°C in medium with or without BFA. Virus titers were determined at 0 h and
8 h postinfection (p.i.). The error bars indicate standard deviations.
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difference in the observed abilities of BFA-resistant GBF1
proteins to rescue replication of a CVB3 3A mutant (Fig. 4)
and a PV 3A mutant (4) can be explained by the use of
different BFA-resistant GBF1 mutants.
We previously showed that overexpression of GBF1 could
rescue secretory pathway transport, as well as cell viability, in
the presence of BFA (4). We compared the abilities of the two
GBF1 mutants to rescue protein secretion and cell viability in
the presence of BFA. To measure protein secretion, cells were
cotransfected with a plasmid expressing Gaussia luciferase with
a secretion signal and the indicated GBF1 mutants or a control
plasmid. The results (Fig. 6A) showed that GBF1-M832L was
more effective in rescuing secretion of Gaussia luciferase in the
presence of BFA than GBF1-A795E. Mutant GBF1-M832L
was also more effective than GBF1-A795E in conferring resis-
tance to cell death induced by various concentrations of BFA
(Fig. 6B). Western blot analysis of cell extracts showed equal
amounts of the two GBF1 mutants, confirming that the ob-
served differences in rescue abilities are unlikely to be due to
differences in expression levels.
DISCUSSION
Enteroviruses replicate their RNA genomes at the outer
surfaces of rearranged, vesicular membrane structures that
accumulate in the cytoplasm of the infected cell. RNA repli-
cation is sensitive to BFA, an inhibitor of ER-to-Golgi network
transport that inhibits Arf activation by interfering with the
activities of large Arf GEFs. Mammalian cells contain three
large BFA-sensitive Arf GEFs: GBF1, BIG1, and BIG2 (13).
In this study, we presented three lines of evidence that GBF1
plays a critical role in CVB3 RNA replication. First, we showed
that RNA replication of CVB3 was insensitive to BFA in
MDCK cells, which express a mutant GBF1 protein (mutation
M832L) that is resistant to BFA (Fig. 1). Second, knockdown
of GBF1 expression by RNA interference inhibited CVB3
RNA replication (Fig. 2). Under the same conditions, no effect
on RNA replication of EMCV, a BFA-insensitive picornavirus,
was observed, demonstrating the specificity of the approach.
Third, overexpression of GBF1, in particular the M832L mu-
tant, rescued the replication of CVB3 in the presence of BFA
(Fig. 3). No rescue was observed with inactive mutants of
FIG. 5. Differential viral-RNA rescue effects of BFA-resistant GBF1 mutants M832L and A795E in HeLa cells. RNA replication of wt and
mutant replicons of PV (A, C, and E) or CVB3 (B, D, and F) in the presence or absence of BFA in nontransfected (control) cells (A and B), in
cells transiently transfected with GBF1 M832L (C and D), or in cells transiently transfected with GBF1 A795E. RNA replication was measured
by determining the amount of Renilla luciferase production.
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GBF1. Overexpression of wt or dominant active forms of Arf
proteins or Rab1B, a small GTPase that recruits GBF1 to
membranes, also failed to rescue CVB3 RNA replication in the
presence of BFA. We have previously shown the importance of
GBF1 for PV RNA replication (4). Together, these data
strongly support a crucial role of GBF1 activity in enterovirus
RNA replication. The role of GBF1 in the replication of pos-
itive-stranded RNA viruses does not seem to be limited to
enteroviruses. Recently, RNA replication of mouse hepatitis
virus, a coronavirus, was also shown to rely on GBF1 activity
(29).
All three large BFA-sensitive Arf GEFs have been shown to
be recruited to membranes by enteroviral nonstructural pro-
teins. GBF1 is recruited to membranes in HeLa cell lysates
expressing the 3A protein (3) and has been recognized to
interact physically with the 3A protein (33). BIG1 and BIG2
have been shown to be recruited to membranes in HeLa cell
lysates expressing the 3CD protein. We observed that CVB3
replication in MDCK cells was insensitive to BFA. In these
cells, the activity of GBF1, but not that of BIG1 and BIG2, is
insensitive to BFA. This finding suggests that the BFA-sensi-
tive functions of BIG1 and BIG2 are not required for entero-
virus RNA replication. A similar conclusion was drawn by
Belov et al. (4), who observed efficient replication of PV in a
BFA-resistant Vero-derived cell line (BER-40). This cell line
contained a BFA-resistant mutation in the Sec7 domain of
GBF1 (A795E) but no mutations in the Sec7 domain of BIG1
or BIG2. Together, these data suggest that BFA blocks entero-
virus replication by inhibiting the activity of GBF1, but not that
of BIG1 and BIG2. Obviously, these data cannot exclude the
possibility that BIG1 and/or BIG2 exerts BFA-independent
functions that are required for enterovirus RNA replication.
However, the observation that knockdown of BIG1 and BIG2
did not affect PV replication in cultured cells (Q. Feng, G.
Belov, and E. Ehrenfeld, unpublished results) argues against
this possibility.
Previously, we showed that the 3A proteins of both CVB3
and PV interact with GBF1 (32, 33). Whether this interaction
is required for viral RNA replication, however, remains to be
established. Three observations suggest that this may be the
case. First, GBF1 was shown to relocalize to the 3A-containing
virus-induced membrane structures at which viral RNA repli-
cation takes place in infected cells (3). Second, overexpression
of the BFA-resistant GBF1-A795E mutant efficiently rescued
RNA replication of wt CVB3 and PV RNA, but not of 3A
mutant viruses that are impaired in interacting with GBF1
(Fig. 5) (4). Third, replication of PV RNA carrying a 3A
mutation that impaired its interaction with GBF1 (mutation
3A-2) was much more sensitive to BFA than wt PV RNA (5).
However, three other observations question the importance of
FIG. 6. BFA-resistant GBF1 mutants M832L and A795E differ in their abilities to rescue protein secretion and cell viability in the presence of
BFA. (A) HeLa cells were cotransfected with plasmid pCMV-Gluc expressing secreted Gaussia luciferase and either a control plasmid or plasmids
expressing GBF1 mutant M832L or A795E. The next day, protein secretion in the presence of 1 g/ml BFA was monitored. The amount of
secreted protein in each sample in the absence of BFA was set at 100%. Western blot analysis (right) showed equal expression of the transfected
GBF1 mutant proteins. (B) HeLa cells were transfected with a control plasmid or plasmids expressing GBF1 mutant M832L or A795E, and
subsequent cell growth in the presence of the indicated amounts of BFA was monitored by a luminescent cell viability assay. The error bars indicate
standard deviations.
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the 3A-GBF1 interaction for efficient viral RNA replication.
We observed no difference in the BFA sensitivities of replica-
tion of wt CVB3 RNA and a mutant RNA carrying the corre-
sponding mutation in 3A (ins[15]S) (data not shown). In ad-
dition, we found that overexpression of the BFA-resistant
mutant GBF1-M832L rescued RNA replication of the 3A mu-
tant viruses of both CVB3 and PV in the presence of BFA, as
well as that of the wt viruses (Fig. 4). Finally, RNA replication
of human rhinoviruses, which contain either a 3A protein that
only weakly interacts with GBF1 (HRV14) or that fails to
interact with GBF1 (HRV2) (32), is also completely abolished
by BFA (reference 17 and data not shown).
In this study, we observed that the GBF1-M832L mutant was
more effective in rescuing protein secretion and cell viability in
the presence of BFA than the GBF1-A795E mutant (Fig. 6);
thus, the former variant is more resistant to BFA than the
latter. This finding may explain why GBF1-M832L was more
effective in rescuing RNA replication of the CVB3 and PV 3A
mutant viruses in the presence of BFA than the GBF1-A795E
mutant (Fig. 5). Although the structure of the GBF1 Sec7
domain has not been resolved, extrapolation of the crystal
structure of the Sec7 domain of another GEF, Arno, com-
plexed with Arf and BFA suggests that the GBF1 M832 and
A795 residues would be located in close proximity and that
both residues participate in van der Waals contacts with BFA.
The potential interactions between 3A, GBF1, Arf-GDP, and
BFA are not understood at the molecular level. For example,
3A binding to GBF1 may occur with quite different kinetics
and affinities than its binding to the GBF1-BFA-Arf complex.
Thus, the expected effects of specific mutations in 3A or in
GBF1 are very difficult to predict. Therefore, it remains to be
established whether the 3A-GBF1 interaction is required to
create the appropriate conditions for viral RNA replication or
whether, alternatively, GBF1 activity is required for viral RNA
replication independent of a functional interaction with 3A. In
the latter case, the 3A-GBF1 interaction may be primarily
involved in the 3A-mediated inhibition of secretory pathway
transport (7, 8, 12, 34), a function that has been implicated in
the viral suppression of cytokine secretion and major histo-
compatibility complex-dependent antigen presentation (9, 11).
Our results showed that knockdown of Arf1 had no effect on
CVB3 replication (Fig. 2). This finding may seem surprising
given the inhibition of replication by BFA and the observed
recruitment of Arf1 to the enterovirus-induced membrane ves-
icles (5). However, the interpretation of this observation
should take into account the results reported by Volpicelli-
Daley et al. (30), who performed a comprehensive study of the
roles of the different Arf isoforms in membrane traffic. In that
study, it was demonstrated that depletion by siRNA of Arf1,
Arf3, Arf4, and Arf5 did not affect any step of membrane
traffic in HeLa cells. However, every combination of the dou-
ble knockdowns of these Arf isoforms yielded a distinct pattern
of defects in secretory and endocytic traffic, demonstrating
clear specificity for Arfs at multiple steps, as well as coopera-
tion of two Arfs at specific sites (e.g., Arf1 and Arf4 were
recognized to be required for anterograde transport between
the ER and the ERGIC, whereas Arf1 and Arf3 were shown to
be important for ERGIC-to-Golgi network transport). Trans-
lation of PV RNA in HeLa cell lysates recruits not only Arf1 to
membranes, but also the other Arf isoforms (except Arf6,
which acts mainly in vesicular processes near the plasma mem-
brane). We have undertaken attempts to investigate CVB3
replication in cells in which pairs of Arfs were knocked down
by RNA interference. Unfortunately, in our hands, these com-
bined knockdowns were rather toxic to the cells. Further ex-
periments are required to better understand the possible roles
of the different Arf isoforms in enterovirus RNA replication.
In conclusion, this study confirms and extends a crucial role
for GBF1 in enterovirus RNA replication. The precise bio-
chemical contribution of GBF1 to virus replication, whether
for a membrane-modifying activity that serves to accumulate
membrane vesicles or for a downstream step that is important
for viral RNA replication, remains to be established.
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